DBV Technologies S.A. (DBV.PA)
EUR 1.33
(3.59%)
EUR 1.33
(3.59%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 89.4 Million EUR | -11.83% |
| 2022 | 101.4 Million USD | -3.65% |
| 2021 | 105.24 Million USD | -22.21% |
| 2020 | 135.29 Million EUR | -20.38% |
| 2019 | 169.92 Million EUR | -10.62% |
| 2018 | 190.11 Million EUR | 9.3% |
| 2017 | 173.93 Million EUR | 42.54% |
| 2016 | 122.02 Million EUR | 144.66% |
| 2015 | 49.87 Million EUR | 65.99% |
| 2014 | 30.04 Million EUR | 8.63% |
| 2013 | 27.66 Million EUR | 53.84% |
| 2012 | 17.98 Million EUR | 89.47% |
| 2011 | 9.48 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 28.55 Million USD | 137.56% |
| 2024 Q2 | 33.84 Million USD | 22.56% |
| 2023 Q1 | 21.16 Million USD | -44.33% |
| 2023 FY | 89.4 Million EUR | -11.83% |
| 2023 Q4 | 12.02 Million USD | -41.92% |
| 2023 Q3 | 20.7 Million USD | -17.45% |
| 2023 Q2 | 25.07 Million USD | 18.48% |
| 2022 Q3 | 18.01 Million USD | -24.37% |
| 2022 Q4 | 38.01 Million USD | 110.99% |
| 2022 Q1 | 16.77 Million USD | -16.58% |
| 2022 Q2 | 23.82 Million USD | 42.05% |
| 2022 FY | 101.4 Million USD | -3.65% |
| 2021 Q1 | 29.63 Million USD | -21.21% |
| 2021 Q2 | 31.13 Million USD | 5.05% |
| 2021 Q3 | 24.36 Million USD | -21.73% |
| 2021 Q4 | 20.1 Million USD | -17.49% |
| 2021 FY | 105.24 Million USD | -22.21% |
| 2020 Q1 | 41.22 Million USD | -15.29% |
| 2020 Q3 | 30.05 Million USD | 13.8% |
| 2020 FY | 135.29 Million EUR | -20.38% |
| 2020 Q4 | 37.61 Million USD | 25.17% |
| 2020 Q2 | 26.4 Million USD | -35.94% |
| 2019 FY | 169.92 Million EUR | -10.62% |
| 2019 Q4 | 48.66 Million EUR | 56.64% |
| 2019 Q1 | 47.84 Million USD | -10.73% |
| 2019 Q2 | 48.49 Million USD | 1.38% |
| 2019 Q3 | 31.06 Million EUR | -35.94% |
| 2018 FY | 190.11 Million EUR | 9.3% |
| 2018 Q4 | 53.59 Million EUR | 4.03% |
| 2018 Q3 | 51.51 Million EUR | 11.17% |
| 2018 Q2 | 46.33 Million USD | -5.21% |
| 2018 Q1 | 48.88 Million USD | 2.52% |
| 2017 Q2 | 44.26 Million USD | 7.06% |
| 2017 Q3 | 46.97 Million USD | 6.12% |
| 2017 Q4 | 47.68 Million USD | 1.51% |
| 2017 FY | 173.93 Million EUR | 42.54% |
| 2017 Q1 | 41.34 Million USD | 14.01% |
| 2016 Q1 | 30.37 Million USD | 58.56% |
| 2016 FY | 122.02 Million EUR | 144.66% |
| 2016 Q4 | 36.26 Million USD | -6.3% |
| 2016 Q3 | 38.7 Million USD | 30.67% |
| 2016 Q2 | 29.61 Million USD | -2.49% |
| 2015 Q1 | 8.03 Million USD | -7.69% |
| 2015 FY | 49.87 Million EUR | 65.99% |
| 2015 Q4 | 19.15 Million USD | 3.92% |
| 2015 Q3 | 18.43 Million USD | 67.12% |
| 2015 Q2 | 11.03 Million USD | 37.27% |
| 2014 Q4 | 8.7 Million USD | -2.33% |
| 2014 FY | 30.04 Million EUR | 8.63% |
| 2014 Q1 | 8.84 Million USD | -7.01% |
| 2014 Q2 | 10.78 Million USD | 21.88% |
| 2014 Q3 | 8.91 Million USD | -17.34% |
| 2013 Q2 | 5.96 Million USD | 1.46% |
| 2013 Q3 | 9.34 Million USD | 56.67% |
| 2013 Q4 | 9.51 Million USD | 1.75% |
| 2013 FY | 27.66 Million EUR | 53.84% |
| 2013 Q1 | 5.88 Million USD | 0.21% |
| 2012 Q3 | 5.71 Million USD | 0.0% |
| 2012 FY | 17.98 Million EUR | 89.47% |
| 2012 Q4 | 5.86 Million USD | 2.66% |
| 2011 FY | 9.48 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -2040.431% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 29.81% |
| Adocia SA | 15.62 Million EUR | -472.051% |
| Aelis Farma SA | 18.81 Million EUR | -375.083% |
| Biophytis S.A. | 14.33 Million EUR | -523.776% |
| Advicenne S.A. | 8.21 Million EUR | -988.324% |
| genOway Société anonyme | 16.73 Million EUR | -434.139% |
| IntegraGen SA | 5.35 Million EUR | -1570.353% |
| Medesis Pharma S.A. | 1.56 Million EUR | -5614.393% |
| Neovacs S.A. | 10.34 Million EUR | -764.363% |
| NFL Biosciences SA | 4.37 Million EUR | -1943.863% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -3133.658% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -5104.169% |
| Sensorion SA | 27.05 Million EUR | -230.475% |
| Theranexus Société Anonyme | 3 Million EUR | -2875.247% |
| TME Pharma N.V. | 5.49 Million EUR | -1526.447% |
| Valbiotis SA | 9.86 Million EUR | -805.926% |
| TheraVet SA | 1.64 Million EUR | -5337.273% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | -339.989% |
| Genfit S.A. | 54.8 Million EUR | -63.137% |
| GeNeuro SA | 14.35 Million EUR | -522.72% |
| Innate Pharma S.A. | 64.57 Million EUR | -38.463% |
| Inventiva S.A. | 120.18 Million EUR | 25.61% |
| MaaT Pharma SA | 21.59 Million EUR | -313.954% |
| MedinCell S.A. | 32.92 Million EUR | -171.569% |
| Nanobiotix S.A. | 58.92 Million EUR | -51.723% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | -279.015% |
| Poxel S.A. | 28.76 Million EUR | -210.815% |
| GenSight Biologics S.A. | 32.66 Million EUR | -173.747% |
| Transgene SA | 31.23 Million EUR | -186.273% |
| Valneva SE | 134.92 Million EUR | 33.736% |